Tourmaline Bio (NASDAQ:TRML - Get Free Report) will likely be announcing its Q4 2024 earnings results before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.91) per share for the quarter.
Tourmaline Bio (NASDAQ:TRML - Get Free Report) last issued its quarterly earnings data on Thursday, March 13th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.91) by $0.05. On average, analysts expect Tourmaline Bio to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Tourmaline Bio Trading Up 4.7 %
TRML traded up $0.77 during trading on Thursday, reaching $17.04. 307,475 shares of the company were exchanged, compared to its average volume of 283,247. The stock has a market cap of $436.96 million, a P/E ratio of -6.04 and a beta of 2.35. The firm has a 50 day moving average of $15.83 and a 200 day moving average of $20.84. Tourmaline Bio has a 52 week low of $11.87 and a 52 week high of $46.36.
Wall Street Analyst Weigh In
TRML has been the subject of a number of analyst reports. HC Wainwright reiterated a "buy" rating and set a $49.00 price target on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Lifesci Capital initiated coverage on Tourmaline Bio in a research report on Monday, February 24th. They set an "outperform" rating and a $58.00 price target for the company. BMO Capital Markets initiated coverage on Tourmaline Bio in a research report on Friday, December 6th. They set an "outperform" rating and a $50.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price target on shares of Tourmaline Bio in a research report on Wednesday, December 11th. Finally, Guggenheim restated a "buy" rating on shares of Tourmaline Bio in a report on Wednesday, December 11th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tourmaline Bio presently has a consensus rating of "Buy" and an average target price of $52.86.
Get Our Latest Analysis on Tourmaline Bio
About Tourmaline Bio
(
Get Free Report)
Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.
Featured Articles
Before you consider Tourmaline Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tourmaline Bio wasn't on the list.
While Tourmaline Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
